Oncodiagnosis panel: 1997. Prostatic carcinoma

Radiographics

Volumn 19, Issue 1, 1999, Pages 185-203

  Lawton, Colleen A ^a   Grignon, David ^b   Newhouse, Jeffrey H ^c   Schellhammer, Paul F ^d   Kuban, Deborah A ^d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Prostate, neoplasms, 844.324; Prostate, therapeutic radiology

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; BONE TUMOR; CANCER STAGING; CASE REPORT; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; HUMAN; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0032608421     PISSN: 02715333     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiographics.19.1.g99ja08185     Document Type: Article

References (102)

1. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50:125-128.
2. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 237-279.
3. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71:3582-3593.
4. Zagars GK, Pollack A, von Eschenback AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997; 79:1370-1380
5. Egawa S, Kawakami T, Nishimaki H, et al. Usefulness and limitation of digital rectal examination and imaging studies in staging prostate cancer. Nippon Hinyokika Gakkai Zasshi 1994; 85:792-801. [Japanese]
6. Quintens H, Chevallier D, Michels JF, et al. Can CT scanner and MRI predict capsular invasion of local cancer of the prostate: a study of 20 radical prostatectomies. Ann Urol 1990; 24:335-339.
7. Friedman AC, Seidmon EJ, Radeck PD, Ley-Toaff A, Caroline DF. Relative merits of MRI, transrectal endosonography and CT in diagnosis and staging of carcinoma of prostate. Urology 1988; 31:530-537.
8. Morgan CL, Calkins RF, Cavalcanti EJ. Computed tomography in the evaluation, staging, and therapy of carcinoma of the bladder and prostate. Radiology 1981; 140:751-761.
9. Perrotti M, Kaufman RP Jr, Jennings TA, et al. Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J Urol 1996; 156:106-109.
10. Huch Boni RA, Boner JA, Debatin JF, et al. Optimization of prostate carcinoma staging: comparison of imaging and clinical methods. Clin Radiol 1995; 50:593-600.
11. Giri PG, Walsh JW, Hazra TA, Texter JH, Koontz WW. Role of computed tomography in the evaluation and management of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1982; 8:283-287.
12. Chelsky MJ, Schnall MD, Seidmon EJ, Pollack HM. Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J Urol 1993; 150(Pt 1):391-395.
13. Jager GJ, Barentsz JO, de la Rosette JJ, Rosenbusch G. Preliminary results of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. Radiologe 1994; 34:129-133.
14. McSherry SA, Levy F. Schiebler ML, Keefe B, Dent GA, Mohler JL. Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography, and magnetic resonance imaging. J Urol 1991; 146:85-89.
15. Chefchaouni MC, Flam T, Cornud F, et al. Results of endorectal MRI in local staging of prostatic cancer: correlation with specimens from prostatectomy - apropos of 47 cases. J Urol 1996; 102:51-55.
16. Bartolozzi C, Menchi I, Lencioni R, et al. Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimens. Eur Radiol 1996; 6:339-345.
17. Bates TS, Cavanagh PM, Speakman M, Gillatt DA. Endorectal MRI using a 0.5 T mid-field system in the staging of localized prostate cancer. Clin Radiol 1996; 51:550-553.
18. Cornud F, Belin X, Flam T, et al. Local staging of prostate cancer by endorectal MRI using fast spin-echo sequences: prospective correlation with pathological findings after radical prostatectomy. Br J Urol 1996; 77:843-850.
19. Osterling JE. Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. Urology 1995; 46(suppl A):26-33.
20. Levran Z, Gonzalez JA, Diokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan, and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75:778-881.
21. Ruiz de la Roja JC, Llorente Abarca C, Romero Cagigal I, et al. Is it possible to do without bone gammagraphy in the staging of prostatic cancer? Acta Urol Espan 1995; 19:123-127.
22. Huncharek M, Muscat J. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Cancer Invest 1995; 13:31-35.
23. Klmient J, Elias B, Svihra J. Levels of prostate-specific antigen, acid phosphatase, alkaline phosphatase, and pain in the prediction of bone metastases in patients with newly diagnosed prostatic carcinoma. Rozhl Chir 1994; 73:300-302.
24. Vijayakumar V, Vijayakumar S, Quadri SF, Blend MJ. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol 1994; 17:432-436.
25. Oommen R, Geethanjali FS, Gopalakrishnan G, et al. Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate. Br J Radiol 1994; 67:469-471.
26. Ploch NR, Brawer MK. How to use prostate-specific antigen. Urology 1994; 43(suppl 2): 27-35.
27. Osterling JE. Using PSA to eliminate the staging radionuclide bone scan: significant economic implications. Urol Clin North Am 1993; 20:705-711.
28. Kahn D, Williams RD, Seldin DW, et al. Radioimmunoscintigraphy with 111 indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994; 152: 1490-1495.
29. Neal CE, Meis LC. Correlative imaging with monoclonal antibodies in colorectal, ovarian, and prostate cancer. Semin Nucl Med 1994; 24:272-285.
30. Chengazi VU, Feneley MR, Ellison D, et al. Imaging prostate cancer with technetium 99m-7E11-C5.3 (CYT-351). J Nucl Med 1997; 38:675-682.
31. Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: positron emission tomography and biopsy correlation. Clin Nucl Med 1996; 21:704-713.
32. Sodee DB, Conant R, Chalfant M, et al. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Clin Nucl Med 1996; 21:759-767.
33. Sanford E, Grzonka R, Heal A, Helal M, Persley L, Tyson I. Prostate cancer imaging with a new monoclonal antibody: a preliminary report. Ann Surg Oncol 1994 1:400-444.
34. Babaian RJ, Sayer E, Podoloff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with 111 indium-labeled monoclonal antibody CYT-356. J Urol 1994; 152:1952-1955.
35. Lu-Yao GL, et al. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol 1997; 157:2219-2222.
36. Mettlin CJ, et al. The National Cancer Data Base report on race, age, and region variation in prostate cancer treatment. Cancer 1997; 80:1261-1266.
37. Partin AW, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997; 277:1445-1451.
38. Schellhammer PF. Patient counselling regarding treatment of T1/2 (A/B) prostate cancer: a personal view. Am J Clin Oncol 1995; 18:532-537.
39. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 1995; 45:476-483.
40. Pollack A, Zagars OK. External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? Urology 1998; 51:258-264.
41. Fukunaga-Jolinson N, Sandler HM, McLaughlin PW, et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38: 311-317.
42. Blasko JC, Walker K, Grimm PD, Ragde H. Prostate specific antigen based disease control following ultrasound guided 125-iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995; 154:1096-1099.
43. Critz FA, Levinson AK, Williams WH, Holladay DA. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. J Clin Oncol 1996; 14:2893-2900.
44. Partin A, Pound C, Clemens J, et al. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20:713-725.
45. Kupelian P, Katcher J, Levin H, et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 1997; 3:78-87.
46. Freedman GM, Hanlon AL, Lee WR, Hanks GE. Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. Int J Radiat Oncol Biol Phys 1996; 35:243-250.
47. Poen JC, Hancock SL, Cox RS, Bagshaw MA. Early stage prostatic cancer in younger men: durable tumor control and favorable prognosis after external beam irradiation at age 60 years or less (abstr). Int J Radiat Oncol Biol Phys 1995; 32:190.
48. American Joint Committee on Cancer. Manual for staging of cancer. 5th ed. Philadelphia, Pa: Lippincott, 1997.
49. Grignon DJ, Sakr WA. Pathologic staging of prostate carcinoma: what are the issues? Cancer 1996; 78:337-340.
50. Sakr WA, Wheeler TM, Blute M, et al. Staging and reporting of prostate cancer: sampling of radical prostatectomy specimen. Cancer 1996; 78:366-368.
51. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:368-374.
52. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994; 44:371-376.
53. Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology 1995; 45:75-80.
54. Epstein JI, Pizoy G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71:3582-3593.
55. Sakr WA, Grignon DJ, Visscher DW, Wolman SR, Crissman JD. Evaluating the radical prostatectomy specimen: a protocol for establishing prognostic parameters and harvesting fresh tissue samples. J Urol Pathol 1995; 3: 355-364.
56. Bostwick DG. Gleason grading of prostate needle biopsies: correlation with grade in matched prostatectomies. Am J Surg Pathol 1994; 18:796-803.
57. Lessells AM, Burnett RA, Howatson SR, et al. Observer variability in the histopathological reporting of needle biopsy specimens of the prostate. Hum Pathol 1997; 28:646-649.
58. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 1996; 47:225-231.
59. Barichello M, Gion M, Bonazza A, et al. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase. Eur Urol 1995; 27:295-300.
60. Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 1992; 70:295-298.
61. Garnick MB, Fair WR. Prostate cancer: emerging concepts, part 1. Ann Intern Med 1996; 125:118-125.
62. Cumming J, Hacking N, Fairhurst J, Ackery D, Jenkins JD. Distribution of bony metastases in prostate carcinoma. Br J Urol 1990; 66: 411-414.
63. Suzuki T, Shimizu T, Kurokawa K, Jimbo H, Sato J, Yamanaka H. Pattern of prostate cancer metastasis to the vertebral column. Prostate 1994; 25:141-146.
64. Fuji Y, Higashi Y, Owada F, Okuno T, Noro A, Arisawa C. Magnetic resonance imaging for the evaluation of prostate cancer metastatic to bone. Nippon Hinyokika Gakkai Zasshi 1995; 86:1261-1265. [Japanese]
65. Fuji Y, Higashi Y, Owada F, Okuno T, Mizuno H, Mizuno H. Magnetic resonance imaging for the evaluation of prostate cancer metastatic to bone. Br J Urol 1995; 75:54-58.
66. Venz S, Hosten N, Friedrichs R, et al. Osteoplastic bone metastases in prostatic carcinoma: magnetic resonance tomography and bone marrow scintigraphy. ROFO 1994; 161: 64-69.
67. Gosfield E III, Alavi A, Kneeland B. Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases. J Nucl Med 1993; 34:2191-2198.
68. Turner JW, Hawes DR, Williams RD. Magnetic resonance imaging for detection of prostate cancer metastatic to bone. J Urol 1993; 149:1482-1484.
69. Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43:649-659.
70. Schild S. Radiation therapy after prostatectomy: now or later? Semin Radiat Oncol 1998; 8:132-139.
71. Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of the prostate: pathologic criteria and clinical significance. Mod Pathol 1997; 10:612-619.
72. Ro JY, Grignon DJ, Ayala AG, et al. Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies. Hum Pathol 1990; 21:593-600.
73. Teichinan JMH, Shabaik A, Demby AM. Mucinous adenocarcinoma of the prostate and hormone sensitivity. J Urol 1994; 151:701-702.
74. Ro JY, El-Naggar A, Ayala AG, et al. Signet-ring cell carcinoma of the prostate. Am J Surg Pathol 1988; 12:453-460.
75. Guerin D, Hasan N, Keen CE. Signet ring cell differentiation in adenocarcinoma of the prostate: a study of five cases. Histopathology 1993; 22:367-371.
76. Christenson WN, Steinberg C, Walsh PC, Epstein JI. Prostatic duct adenocarcinoma: findings at radical prostatectomy. Cancer 1991; 67:2118-2124.
77. Lee SS. Endometrioid adenocarcinoma of the prostate: a clinicopathologic and immunohistochemical study. J Surg Oncol 1994; 55:235-238.
78. Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate. 1. A clinicopathologic study of 20 cases. Cancer 1987; 59: 1803-1809.
79. Osterling JE, Hauzear CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological, and immunohistological study of 27 patients. J Urol 1992; 147: 804-809.
80. Rubenstein JH, Katin MJ, Mangano MM, et al. Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 1997; 20:376-380.
81. Shannon RL, Ro JY, Grignon DJ, et al. Sarcomatoid carcinoma of the prostate: a clinicopathologic study of 12 cases. Cancer 1992; 69:2676-2682.
82. Lauwers GY, Schevchuk M, Armenekas N, Reuter VE. Carcinosarcoma of the prostate. Am J Surg Pathol 1993; 17:342-349.
83. Dundore PA, Cheville JC, Nascimento AG, Farrow GM, Bostwick DG. Carcinosarcoma of the prostate: report of 21 cases. Cancer 1995; 76:1035-1042.
84. Dorsam J, Kalble T, Riedasch G, Staehler G. The value of diagnostic imaging in benign prostatic hyperplasia and prostatic cancer. Radiologe 1994; 34:101-108.
85. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48:398-405.
86. Pilepich MV, Caplan R, Byhardt CA, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997; 15:1013-1021.
87. Pilepich MV, Krall JM, Al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45:616-623.
88. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337:295-300.
89. Vicini FA, Horwitz EM, Gonzalez J, Martinez AA. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J Urol 1997; 158: 319-325.
90. Jorgensen T, Muller C, Kaalhus O, Danielsen HE, Tever KJ. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer - experience from the Scandinavian Prostatic Cancer Group study no. 2 (SPCG-2). Eur Urol 1995; 28:40-46.
91. Knudson G, Grinis G, Lopez-Majano V, et al. Bone scan as a stratification variable in advanced prostate cancer. Cancer 1991; 68:316-320.
92. Soloway MS, Ishikawa S, van der Zwaag R, Todd B. Prognostic factors in patients with advanced prostate cancer. Urology 1989; 33 (suppl 5):53-56.
93. Soloway MS, Hardemann SW, Hickey D, et al. Stratification of patients with metastatic cancer based on extent of disease on initial bone scan. Cancer 1988; 61:195-202.
94. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46:142-148.
95. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:1566-1572.
96. Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159:149-153.
97. Small EJ, Baron A, Fippon L, Apodaca D. Ketokonazole retains activity in "hormone refractory" prostate cancer. J Urol 1997; 157: 1204-1207.
98. Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996; 14:1756-1764.
99. Pienta KJ, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005-2012.
100. Haas OP, Sakr WA. Epidemiology of prostate cancer. CA Cancer J Clin 1997; 47:273-287.
101. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47:5-27.
102. Porter A, McEwan AJ, Powe JE. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25:805-813.